Astrazeneca (AZN) Inventory (2016 - 2026)

Astrazeneca has reported Inventory over the past 17 years, most recently at $6.6 billion for Q1 2026.

For Q1 2026, Inventory rose 11.66% year-over-year to $6.6 billion; the TTM value through Mar 2026 reached $6.6 billion, up 11.66%, while the annual FY2025 figure was $6.6 billion, 24.0% up from the prior year.
Inventory for Q1 2026 was $6.6 billion at Astrazeneca, roughly flat from $6.6 billion in the prior quarter.
Over five years, Inventory peaked at $7.6 billion in Q1 2022 and troughed at $4.7 billion in Q4 2022.
A 5-year average of $5.8 billion and a median of $5.7 billion in 2024 define the central range for Inventory.
On a YoY basis, Inventory climbed as much as 125.56% in 2022 and fell as far as 51.77% in 2022.
Year by year, Inventory stood at $4.7 billion in 2022, then rose by 15.43% to $5.4 billion in 2023, then dropped by 2.51% to $5.3 billion in 2024, then grew by 24.0% to $6.6 billion in 2025, then grew by 0.2% to $6.6 billion in 2026.
Business Quant data shows Inventory for AZN at $6.6 billion in Q1 2026, $6.6 billion in Q4 2025, and $6.6 billion in Q3 2025.

Peer Comparison